Zoetis (NYSE:ZTS) Upgraded by Wall Street Zen to “Buy” Rating

Zoetis (NYSE:ZTS) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Friday.

Other equities analysts have also issued research reports about the stock. BTIG Research reaffirmed a “buy” rating and set a $160.00 price objective on shares of Zoetis in a research report on Wednesday, December 3rd. KeyCorp assumed coverage on shares of Zoetis in a report on Thursday, November 20th. They set a “sector weight” rating on the stock. Morgan Stanley set a $160.00 price objective on shares of Zoetis in a research note on Thursday, December 18th. JPMorgan Chase & Co. lowered their target price on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. Finally, UBS Group cut their target price on Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a report on Wednesday, November 5th. Five analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat, Zoetis has an average rating of “Hold” and a consensus price target of $152.91.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $124.04 on Friday. The business has a fifty day simple moving average of $123.58 and a 200 day simple moving average of $138.43. The company has a current ratio of 3.64, a quick ratio of 2.28 and a debt-to-equity ratio of 1.31. Zoetis has a 1 year low of $115.25 and a 1 year high of $177.40. The firm has a market cap of $54.66 billion, a price-to-earnings ratio of 20.88, a P/E/G ratio of 2.16 and a beta of 0.97.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. The company had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.42 billion. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The business’s quarterly revenue was up .5% on a year-over-year basis. During the same period last year, the business earned $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, sell-side analysts predict that Zoetis will post 6.07 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Zoetis

Hedge funds and other institutional investors have recently modified their holdings of the stock. Tyche Wealth Partners LLC acquired a new stake in Zoetis in the 4th quarter valued at $216,000. Patton Fund Management Inc. boosted its stake in shares of Zoetis by 24.1% in the 4th quarter. Patton Fund Management Inc. now owns 1,780 shares of the company’s stock valued at $224,000 after purchasing an additional 346 shares in the last quarter. Cove Private Wealth LLC grew its holdings in shares of Zoetis by 12.1% in the 4th quarter. Cove Private Wealth LLC now owns 5,842 shares of the company’s stock worth $735,000 after purchasing an additional 632 shares during the last quarter. Assetmark Inc. increased its position in shares of Zoetis by 143.0% during the 4th quarter. Assetmark Inc. now owns 19,862 shares of the company’s stock worth $2,499,000 after purchasing an additional 11,689 shares in the last quarter. Finally, Norris Perne & French LLP MI lifted its holdings in Zoetis by 24.8% during the 4th quarter. Norris Perne & French LLP MI now owns 63,050 shares of the company’s stock valued at $7,933,000 after purchasing an additional 12,534 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.